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The durability of antibody responses to severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), the virus responsible for coronavi-
rus disease (COVID-19), is of scientifi c and strategic 
interest for public health systems worldwide. Af-
ter SARS-CoV-2 infection, antibodies are produced 
against multiple viral epitopes, including the nu-
cleocapsid (N) protein, which is highly immuno-
genic and abundantly expressed (1). A key concern 
is the potential for rapid waning of antibodies and 
seroreversion (loss of detectable antibodies), as seen 
with other novel betacoronaviruses (2), which might 
represent declining immunity and could compro-
mise serosurveillance. 
Frontline healthcare workers are a vital popula-
tion for serosurveillance because they are at greater 
risk than the general population. We describe fi nd-
ings from a serosurveillance study conducted in Lon-
don, UK, by Public Health England (PHE).
The Study
We conducted prospective serosurveillance of health-
care professionals in secondary care settings across 
London beginning March 30, 2020. Healthcare work-
ers were recruited by hospital research teams and 
provided written informed consent. Demographic, 
occupational, and clinical data were collected at base-
line, including self-reported previous laboratory-con-
fi rmed COVID-19. Participants provided blood sam-
ples and completed symptom surveys at baseline and 
2-weekly intervals until July 21, 2020, reporting any 
new illness or COVID-19 diagnosis. Blood samples 
were centrifuged and frozen locally; PHE then test-
ed serum samples by using the Elecsys Anti-SARS-
CoV-2 total antibody assay (Roche, https://www.
roche.com), according to the manufacturer’s instruc-
tions. This test is an electrochemiluminescence immu-
noassay for antibodies targeting the N protein (IgG, 
IgM, or IgA) and produces a numeric cutoff index de-
rived from comparison of the sample and calibrator 
signals (3). The surveillance protocol was approved 
by the PHE Research Ethics Governance Group (R&D 
REGG Ref: NR0192, March 31, 2020).
We compared differences in seropositivity be-
tween groups by using χ2 tests and multivariable 
logistic regression to provide adjusted odds ratios 
(aORs). We estimated biweekly seroconversion and 
seroreversion rates and binomial 95% CIs. We ana-
lyzed trends in individual-level antibody responses 
beginning 4 weeks after the fi rst positive antibody 
test, which allowed time for responses to stabilize. 
We used mixed effects regression to analyze trends 
in log antibody titers and assessed fi xed effects for 
differences in antibody response through likelihood 
ratio tests.
Surveillance involved 1,069 participants from 4 
hospitals: Charing Cross (n = 192), Northwick Park (n 
= 217), Royal Free (n = 126), and St. George’s (n = 534). 
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Prospective serosurveillance of severe acute respiratory 
syndrome coronavirus 2 in 1,069 healthcare workers in 
London, UK, demonstrated that nucleocapsid antibody 
titers were stable and sustained for <12 weeks in 312 se-
ropositive participants. This fi nding was consistent across 
demographic and clinical variables and contrasts with re-
ports of short-term antibody waning.
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Of these, 850 participants had >4 sampling visits and 
395 >6 sampling visits (over 10–12 weeks of follow-
up). Overall, 312 (29%) participants had >1 positive an-
tibody test (95% CI 26%–32%); of those, 181 (58%) had 
>8 weeks and 42 (13%) 12 weeks of follow-up after the 
first positive test (Appendix Table 1, https://wwwnc. 
cdc.gov/EID/article/27/4/20-4554-App1.pdf). Sero-
positivity varied between hospitals (p = 0.042), from 
25% to 35%. In total, 109 (10.2%) participants self-re-
ported laboratory-confirmed COVID-19, 407 (32%) re-
ported respiratory illness, 5 (0.47%) reported hospital-
ization, and 794 (61%) did not report illness.
We observed no difference in seropositivity by 
sex, profession, performance of aerosol-generating 
procedures, employment in the emergency depart-
ment, or immunocompromised status (Appendix 
Figure. log antibody titers over time in participants with >1 positive test result by subgroups in study of nucleocapsid-antibody response 
in healthcare workers, London, UK. Subgroups are as follows: A) no self-reported illness (n = 99), B) coronavirus disease (COVID-19) 
diagnosis (n = 94), C) respiratory illness (n = 175), D) other illness (n = 43), E) immunocompromised (n = 6), F) general hospital 
employee (n = 204), G) emergency department employee (n = 71), H) intensive care unit employee (n = 38), I) age <40 years (n = 185), 
J) age >40 years (n = 127), K) male sex (n = 95), L) female sex (n = 217). Times are with respect to the date of the first positive test 
(week 0), and week 4 is indicated by dashed lines; previous negative results are also included. Individual responses are indicated by 
blue lines; mean titers with 95% CI for the mean are shown in red.
Table 2). Participants 25–34 years of age had higher 
odds of seropositivity than those 35–44 years of age 
(aOR 1.57, 95% CI 1.09–2.26), but little difference 
was seen among older age groups. Those working in 
intensive care units had lower odds of seropositivity 
than participants from other hospital departments 
(aOR 0.58, 95% CI 0.38–0.91).
Most seropositive participants tested positive at 
baseline (279/312, 89%). Only 33 participants sero-
converted during follow-up, corresponding to a bi-
weekly rate of 1.2% (95% CI 0.8%–1.7%). We observed 
4 seroreversions, corresponding to a biweekly rate of 
0.4% (95% CI 0.1%–0.9%).
log antibody titers remained stable over time in 
seropositive participants, and little within-individual 
variability was observed (Figure). The general trend 
across all subgroups was a slight increase over time, 
although data are sparse for some groups.
We modeled trends beginning 4 weeks after the 
first positive antibody test. The mean weekly change 
was a 3.9% increase (95% CI 3.2%–4.6%). The model 
enables individual variability and thus estimates a 
distribution in trends, which ranged from a 0.5% de-
crease to an 8.5% increase per week, at 1 SD below/
above the mean.
Baseline response or subsequent trend did not 
differ by work setting, clinical symptoms, or laborato-
ry-confirmed COVID-19; minimum likelihood ratio p 
value was 0.46. Participants >40 years of age had 30% 
higher antibody titers at baseline (p = 0.08) but less 
increase over time; weekly increase was 2.9% (95% CI 
1.8%–4.0%) compared with 4.5% (95% CI 3.6%–5.4%) 
in those <40 years of age (p = 0.028). We observed sim-
ilar baseline titers between women and men (p = 0.61) 
but different trends; women demonstrated a weekly 
increase of 3.4% (95% CI 2.6%–4.2%) compared with 
5.2% (95% CI 3.8%–6.6%) in men (p = 0.035).
Conclusions
In this study, N-antibody seropositivity was 29% 
among healthcare workers, and a small, sustained 
rise in antibody titers occurred over 12 weeks. The in-
crease could be explained by the natural boosting of 
antibodies through repeated SARS-CoV-2 exposure; 
however, we saw no evidence of sporadic, sharp in-
creases in antibodies in seropositive participants, and 
we observed little deviation from an overall linear 
trend. High initial seroprevalence and low subse-
quent seroconversion rates (Appendix Figures 1, 2) 
indicate that most exposures occurred before surveil-
lance began. The low seroincidence after April might 
be attributable to changes in hospital infection control 
practices and national lockdown.
These findings demonstrate the short-term stabil-
ity of N-antibody titers in healthcare staff, regardless 
of demographic or clinical differences. Seropositive 
participants not reporting any COVID-19 diagnosis 
or previous illness (even mild or atypical symptoms) 
demonstrated the same antibody trends as those who 
reported symptoms or laboratory-confirmed CO-
VID-19, thereby supporting N-antibody testing as a 
reliable surveillance indicator. Although serorever-
sion was uncommon, such rates, if sustained, might 
be concerning in the long term.
Although cross-reactivity against the N protein 
has been observed and appears more prevalent than 
cross-reactivity against the spike (S) protein (E.M. An-
derson, unpub. data, https://doi.org/10.1101/2020.1
1.06.20227215; C.F. Houlihan, unpub. data, https://
doi.org/10.1101/2020.06.08.20120584), the risk for 
false positives because of preexisting human coro-
navirus antibodies seems low on the basis of avail-
able data. The Elecsys assay demonstrated >99.5% 
specificity in 2 independent evaluations using large 
numbers of prepandemic control samples (3,4) and 
demonstrated high positive predictive value at an es-
timated 10% seroprevalence. Nonetheless, this study 
is limited by use of a single immunoassay, by self-
reported data on COVID-19 diagnosis, and by limited 
testing early in the pandemic.
Several studies have demonstrated substantial 
declines in antibody titers over 3–5 months by us-
ing anti-S or anti–receptor-binding domain immu-
noassays (5–9). Although findings are not consis-
tent across all reports (6,10), disparities could be 
explained by shorter follow-up periods that missed 
later decline. In contrast, the few studies conduct-
ing serial testing for >3 months by using N-anti-
body assays, particularly the Elecsys assay, report 
that titers remained steady (9) or increased (11; F. 
Muecksch, unpub. data, https://doi.org/10.1101/ 
2020.08.05.20169128). These studies were limited 
by small sample sizes, single-site recruitment, and 
few time points with long sampling intervals. Our 
study replicates these findings in a large, multi-
center cohort with frequent sampling and focuses 
on healthcare workers with mostly asymptomatic 
or mild disease, with robust statistical analysis to 
demonstrate consistent findings across all groups. 
These data can usefully inform serosurveillance 
strategies during the second wave.
For unknown reasons, N-antibodies appear 
highly stable in the short term, despite demonstrat-
ing no functional role; whether this stability would 
persist over longer follow-up periods remains to 
be answered. Although less useful as correlates of 
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immunity, N-antibodies could serve a critical role in 
serosurveillance as S-based vaccines are deployed, 
helping to distinguish infection-induced seroconver-
sion from vaccine-induced seroconversion.
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Appendix Table 1. Numbers and percentages of seropositive participants (n = 312) by length of follow-up after first positive 
antibody test in study of N-antibody response in healthcare workers, London, UK 
Weeks of follow-up after first positive test Frequency Percentage Cumulative percentage 
0 18 5.77 5.77 
2 12 3.85 9.62 
4 22 7.05 16.67 
6 79 25.32 41.99 
8 51 16.35 58.33 
10 88 28.21 86.54 
12 42 13.46 100.00 
Total 312 100.00 100.0 
 
Appendix Table 2. Results from multivariable logistic regression examining association of various demographic, occupational, and 
clinical factors on the odds of seropositivity in study of SARS-CoV-2 N-antibody response in healthcare workers, London, UK* 
Variable aOR of seropositivity (95% CI) p value 
Age group, y 
  
 15–24 1.41 (0.70–2.84) 0.331 
 25–34 1.57 (1.09–2.26) 0.016 
 35–44 1 
 
 45–54 1.26 (0.82–1.96) 0.294 
 >55 0.93 (0.47–1.84) 0.843 
Sex 
  
 M 1 
 
 F 0.89 (0.64–1.24) 0.497 
Professional role 
  
 Doctor 1 
 
 Nurse 0.92 (0.65–1.30) 0.633 
 Other 1.21 (0.82–1.77) 0.341 
Emergency department setting 0.95 (0.66–1.36) 0.761 
ICU setting 0.58 (0.38–0.91) 0.016 
Aerosol-generating procedures 1.08 (0.78–1.48) 0.655 
Immunocompromised 1.19 (0.44–3.24) 0.736 
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Appendix Figure 1. Percentage of positive samples by study site and 2-week periods with binomial 95% 
CI in study of severe acute respiratory syndrome coronavirus 2 N-antibody response in healthcare 
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Appendix Figure 2. Percentage of positive samples by hospital department and 2-week periods with 
binomial 95% CI in study of severe acute respiratory syndrome coronavirus 2 N-antibody response in 
healthcare workers, London, UK. Sample sizes are indicated above each bar. ICU, intensive care unit. 
